A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas. - Related Studies

A Phase 3 Trial of ALIMTA (LY231514, Pemetrexed) Plus GEMZAR Versus GEMZAR in Patients With Unresectable or Metastatic Cancer of the Pancreas.

This study has been completed.

Study NCT00035035. Last updated on July 18, 2006. Information provided by Eli Lilly and Company

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Pancreatic Neoplasms
		Metastases, Neoplasm

2	Additional conditions recognized in this trial
		Neoplasm Metastasis
		Neoplasms

3	More general conditions related to this trial
		Digestive System Diseases
		Digestive System Neoplasms
		Endocrine Gland Neoplasms
		Endocrine System Diseases
		Neoplasms by Site
		Neoplastic Processes
		Pancreatic Diseases
		Pathologic Processes

4	Interventions listed in this trial
		GEMZAR
		ALIMTA

5	Additional drug interventions recognized in this trial
		Gemcitabine
		Pancrelipase
		Pemetrexed

6	More general drug interventions related to this trial
		Anti-Infective Agents
		Antimetabolites
		Antimetabolites, Antineoplastic
		Antineoplastic Agents
		Antiviral Agents
		Enzyme Inhibitors
		Folic Acid Antagonists
		Gastrointestinal Agents
		Immunologic Factors
		Immunosuppressive Agents
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Physiological Effects of Drugs
		Radiation-Sensitizing Agents
		Therapeutic Uses

7	Sponsors listed in this trial
		Eli Lilly and Company